Evidence map›Paper›PMID 24368892›Full record

ArticleInternational medical case reports journal2013

Isolated granulocytic sarcoma of the nasopharynx: a case report and review of the literature.

Prakash Vishnu, Ravindra Reddy Chuda, Dick G Hwang, David M Aboulafia

Open access · goldAbstract readCase Reports
In one paragraph

Article in International medical case reports journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. OncoTargets and therapy · 2020
    Article
  3. Article
  4. Article
  5. The progression of CD56Oncology letters · 2016
    Article
  6. Myeloid sarcoma: An unusual and rare laryngeal presentation.International journal of surgery case reports · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Prakash VishnuFloyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, WA, USA.
Ravindra Reddy ChudaDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Dick G HwangDepartment of Pathology, Virginia Mason Medical Center, Seattle, WA, USA.
David M AboulafiaFloyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, WA, USA ; Division of Hematology, University of Washington, Seattle, WA, USA.
Virginia Mason Medical Center · USUniversity of Kansas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulocytic sarcoma (GS) is a rare extramedullary manifestation of acute myeloid leukemia (AML). It may also represent blastic transformation of myelodysplastic syndromes or myeloproliferative neoplasms. Although usually seen in the context of advanced and poorly controlled disease, it may also present as the first manifestation of illness, without concurrent bone marrow or blood involvement. In the medical literature, chloroma and GS are terms that have been used interchangeably with myeloid sarcoma. GS usually manifests as soft tissue or bony masses in several extracranial sites, such as bone, periosteum, and lymph nodes; involvement of the head and neck region is uncommon. We report a case of a woman with insidious onset of progressive nasal congestion and diminished hearing who was diagnosed with an isolated GS of the nasopharynx. With involved field radiotherapy, she achieved a complete remission of 12-months duration before being diagnosed with overt AML. She has remained disease-free for greater than 18 months following induction and consolidation chemotherapy. Through a MEDLINE®/PubMed® search we identified an additional 13 cases of nasopharyngeal GS. The median age was 37 years (range 1 to 81 years). The cases were equally distributed among the sexes. The most common presenting symptoms were conductive hearing loss and sinonasal congestion. Isolated GS was identified in six cases, and the median time from diagnosis of GS to AML was 12 months (range 3 to 48 months). The treatment varied, but responses were seen in all the patients who received chemotherapy with or without radiotherapy.

Indexed as

acute myeloid leukemiachloromamyeloid sarcomatreatment

Identifiers

PMID24368892
PMCPMC3869915
OpenAlexW1988750755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.